C15 Fatty Acid: What It Is and Its Health Benefits

Pentadecanoic acid, commonly called C15:0 or the C15 fatty acid, is an odd-chain saturated fatty acid found primarily in dairy fat and some fish. It has attracted growing scientific interest because higher levels in the bloodstream are consistently linked to lower risks of heart disease, type 2 diabetes, and liver disorders, and researchers have proposed it may qualify as an essential nutrient your body cannot make enough of on its own.¹ That proposal is still debated, but the evidence base is substantial enough that C15:0 has moved well beyond nutritional curiosity.

What C15:0 Actually Is

Most dietary fats you encounter are even-chain fatty acids, meaning their carbon backbones are 14, 16, or 18 carbons long. C15:0 breaks that pattern with 15 carbons, placing it in the “odd-chain” category alongside C17:0 (heptadecanoic acid). Odd-chain fatty acids make up a tiny fraction of total fat intake, which is one reason they were overlooked for decades. They were assumed to be biologically inert metabolic oddities. That assumption has changed sharply in recent years.

Your body does produce small amounts of C15:0 through a process called alpha-oxidation, but research indicates the quantities are not sufficient to meet physiological needs. As one review put it, C15:0 “is not synthesized in sufficient quantities endogenously, so it must be provided by the diet, mainly through dairy fat, although other types of food can also contribute.”² That dependence on dietary intake is one of the core criteria for classifying a nutrient as essential, though the debate around that label is far from settled.

How C15:0 Works Inside Cells

C15:0 appears to operate through two primary mechanisms at the cellular level: strengthening cell membranes and supporting mitochondrial function. Because it is a saturated fat with an odd-chain structure, it integrates into cell membranes in a way that increases their stability without making them excessively rigid. Researchers have described this as helping cells resist a form of damage called ferroptosis, in which weakened membranes undergo uncontrolled oxidation that ultimately kills the cell.³ C15:0 resists the kind of oxidative breakdown that more fragile unsaturated fats are vulnerable to, helping preserve the structural integrity of the membrane.⁴

On the mitochondrial side, cell-based studies show that C15:0 lowers the production of damaging reactive oxygen species inside mitochondria. At concentrations between 10 and 50 micromolar, supplemented cells produced roughly half the reactive oxygen species compared to untreated controls.⁵ Less oxidative stress in mitochondria translates to better energy production and fewer of the downstream cascades that contribute to chronic inflammation and cell aging.

Beyond the membrane and mitochondria, C15:0 activates several molecular signaling pathways. It acts as a dual agonist for two receptors involved in fat metabolism, activates an enzyme that senses cellular energy status, and inhibits a specific protein involved in inflammation and gene regulation.⁶ That combination of targets may explain why C15:0 shows up in studies across such a wide range of health conditions. It is not acting on one narrow pathway but on several interconnected ones that touch inflammation, metabolism, and cell growth.

Cardiovascular Health

The most robust evidence for C15:0’s benefits comes from cardiovascular research. A narrative review summarizing prospective studies found that higher circulating C15:0 was associated with roughly a 25% lower risk of cardiovascular disease per interquartile range increase in one large study, and a meta-analysis by Trieu and colleagues found about a 12% lower risk of total cardiovascular events in individuals with high versus low circulating C15:0 levels.⁷ The relationship appeared to follow a linear dose-response pattern, meaning higher levels tracked with progressively lower risk rather than leveling off at some threshold.

These are observational findings, so they do not prove C15:0 directly prevents heart attacks or strokes. People with higher C15:0 levels tend to eat more full-fat dairy, and dairy consumption itself comes bundled with other nutrients, lifestyle patterns, and socioeconomic factors. Still, the consistency of the association across multiple populations and study designs gives it more weight than a single headline result would deserve.

Type 2 Diabetes and Metabolic Risk

The diabetes link is where the evidence gets particularly interesting, and also where it gets complicated. A large prospective study in the European population found that higher blood levels of C15:0 (measured in phospholipids) were associated with substantially lower diabetes risk in women. Women in the highest category had roughly 80% lower risk compared to those in the lowest category. But the same association did not hold in men, where the relationship was nonlinear and showed no clear protective pattern.⁸

That sex difference is not fully understood, and it complicates the straightforward “more C15:0, less diabetes” narrative. It could reflect differences in how men and women metabolize odd-chain fatty acids, in their hormonal environments, or in how C15:0 gets packaged into different blood lipid fractions. What the data do consistently show, across multiple studies and both sexes, is that higher circulating levels of odd-chain fatty acids as a group are associated with better cardiometabolic profiles overall.⁵

Liver Health

In animal studies of fatty liver disease, C15:0 supplementation showed noteworthy protective effects. In a model that produces liver fibrosis, inflammation, and iron overload, animals receiving daily oral C15:0 did not progress to the more severe bridging fibrosis stage that untreated diseased animals developed. They also showed less liver iron accumulation within specialized immune cells and lower inflammatory markers overall.⁹

These are animal results, not human clinical trials, and the gap between preventing fibrosis in a lab model and treating fatty liver disease in people is large. But given that nonalcoholic fatty liver disease affects a growing proportion of the population and has limited treatment options, the direction of the finding has generated real interest among hepatology researchers.

Neuroprotection and Brain Health

A newer area of C15:0 research involves the brain. In laboratory assays, C15:0 was found to inhibit two enzymes relevant to neurodegenerative disease. It blocked fatty acid amide hydrolase (FAAH) with strong potency and also inhibited monoamine oxidase B (MAO-B), an enzyme whose overactivity is linked to neuroinflammation and dopamine breakdown in conditions like Parkinson’s disease.¹⁰ Both targets have demonstrated relevance to amyloid-beta formation and hippocampal protection in prior research.

This line of inquiry came partly from studying bottlenose dolphins, which develop amyloid plaques similar to those seen in Alzheimer’s disease but are challenging to study with dietary interventions. The enzyme-inhibition data is purely in vitro at this stage, so it remains speculative whether dietary C15:0 meaningfully reaches the brain in concentrations high enough to reproduce these effects. Still, the dual inhibition of FAAH and MAO-B is unusual for a naturally occurring dietary fatty acid and suggests a mechanism worth investigating further.

How C15:0 Stacks Up Against Omega-3

One of the more provocative claims in the C15:0 literature is that it performs as well as or better than omega-3 fatty acids across certain measures. A head-to-head comparison of pure C15:0 against EPA (eicosapentaenoic acid, one of the two main omega-3s) tested both across 12 human cell-based disease models spanning inflammation, cancer, and metabolic dysfunction. C15:0 was non-toxic at all tested concentrations and showed clinically relevant activity across 36 biomarkers in 10 of the 12 systems. EPA, by contrast, was toxic to four cell systems at the highest tested concentration. And while the two shared 12 overlapping activities, C15:0 had an additional 28 that EPA did not, primarily anti-inflammatory effects.¹¹

A separate study compared C15:0 to rapamycin, an immunosuppressant drug known for its longevity-promoting effects in animal models. The two compounds shared 24 clinically relevant activities across 10 cell systems, including anti-inflammatory, antifibrotic, and anticancer activities, at their optimal doses.² Rapamycin has serious side effects that make it impractical as a daily supplement for healthy people. A dietary fatty acid that mimics even a portion of its cellular activity without those downsides would be significant if the effects translate from cells to whole organisms.

These comparisons are compelling in a laboratory setting, but it is worth noting that omega-3 fatty acids have decades of human clinical trial data supporting their cardiovascular benefits. C15:0 does not yet have that depth of interventional evidence. The cell-based studies suggest C15:0 is a powerful molecule, but the practical question of whether taking it as a supplement produces measurable health improvements in people is still being answered.

The Essential Fatty Acid Question

For a nutrient to be classified as essential, it generally needs to meet three criteria: the body cannot make enough of it, deficiency leads to disease, and restoring intake reverses or prevents that disease. Researchers have made a formal case that C15:0 meets all three. Circulating C15:0 is primarily driven by dietary intake rather than endogenous production. Lower circulating concentrations are associated with higher mortality and worse metabolic profiles. And supplementation repairs cellular and mitochondrial function in both cell and animal models.¹²

Not everyone in the field is convinced. Some researchers point out that the body can produce small amounts through alpha-oxidation of longer even-chain fats, which technically weakens the “cannot be made endogenously” criterion. There is also the challenge that much of the evidence tying low C15:0 to disease comes from observational studies, where dairy intake (the main source) is entangled with broader dietary patterns. A review specifically examining C15:0’s essentiality acknowledged that dairy remains the primary dietary source and that endogenous production falls short, but the classification question remains formally unresolved in mainstream nutrition science.

Where to Get C15:0 in Your Diet

The dominant dietary source of C15:0 is dairy fat, particularly whole milk, butter, and full-fat cheese. This creates an ironic tension with the dietary guidelines of the past several decades. Over a 20-year period following initial recommendations to reduce saturated fat intake, average whole-fat milk consumption in the United States dropped more than fourfold. Yet during the same period, rates of obesity, type 2 diabetes, metabolic syndrome, and nonalcoholic fatty liver disease all increased.¹³ The correlation is not proof of causation, but it has led to calls to refine dietary fat guidelines so they distinguish between even-chain saturated fats (like palmitic acid, which raises cardiovascular risk) and odd-chain saturated fats like C15:0 (which appear protective).

Some fish and ruminant meats also contain small amounts, but dairy fat remains by far the richest source. For people who avoid dairy, this poses a problem. A supplement product called FA15 (pure pentadecanoic acid in capsule form) has been developed and is commercially available, though long-term human safety and efficacy data from large clinical trials is still limited.

For those interested in plant-based or non-animal sources, the picture is sparse. Some microalgae can produce odd-chain fatty acids when fed specific carbon sources. Research using the microalga Schizochytrium limacinum showed that when grown on waste-derived volatile fatty acids like valeric and propionic acid, it produced biomass containing about 25% odd-chain fatty acids alongside DHA.¹⁴ That is a proof-of-concept for industrial production, not a food you can buy today, but it signals a potential future path for vegan-friendly C15:0.

Why Saturated Fat Guidelines Miss the Nuance

Current dietary guidelines in most countries treat saturated fat as a single category to minimize. That made sense when the primary concern was the effect of palmitic acid (C16:0) and stearic acid (C18:0) on LDL cholesterol and cardiovascular risk. But grouping all saturated fats together means that advice to cut dairy fat inadvertently reduces intake of C15:0 as well, even though the evidence suggests C15:0 has opposite health associations from its even-chain neighbors.

This matters practically because many people who follow low-fat dietary advice and choose skim milk over whole milk, or avoid butter in favor of plant oils, may be unintentionally lowering their C15:0 intake. Whether that contributes meaningfully to disease risk is still uncertain at the population level, but researchers have increasingly argued that nutrition policy should acknowledge the distinction. Several published papers now explicitly call for refined saturated-fat guidelines that separate even-chain and odd-chain types.

The counterargument is that whole-fat dairy comes packaged with substantial amounts of even-chain saturated fats, so telling people to eat more butter for the C15:0 would increase their palmitic acid intake too. This is partly why isolated C15:0 supplementation has attracted attention. It offers a way to get the odd-chain benefits without the even-chain baggage, though the evidence base for supplementation specifically is far thinner than for dairy-associated C15:0 in observational studies.

What We Do Not Know Yet

For all the enthusiasm in the research community, C15:0 science has gaps that are worth understanding. Nearly all the cardiovascular and metabolic data comes from observational studies measuring blood levels of C15:0 as a biomarker. Blood C15:0 is a reliable indicator of dairy fat intake, which means these studies may be partially capturing the benefits of dairy consumption broadly rather than C15:0 specifically. Disentangling the fatty acid from its food matrix is a challenge that only randomized controlled trials with isolated C15:0 supplements can fully address, and those trials are still in early stages.

The sex differences in the diabetes data also deserve more attention. A protective association appearing strongly in women but not in men suggests the biology is more complex than “more C15:0 equals less disease.” Hormonal influences, differences in fat storage and metabolism, and variation in gut microbiome processing of odd-chain fats are all plausible explanations, but none has been confirmed.

There is also the dose question. The cell-based studies showing mitochondrial benefits used concentrations in the 10 to 50 micromolar range. Whether dietary intake or standard supplementation achieves those concentrations in relevant human tissues, particularly in the brain, is not established. A molecule that performs well in a cell culture dish does not always reach the right tissues at the right concentrations in a living person. The neuroprotection research, while exciting, is the most preliminary of the C15:0 claims and will need animal and then human studies before any confident conclusions can be drawn.

Finally, C15:0 research has been driven in large part by a small group of investigators, several of whom are connected to the company producing the FA15 supplement. That does not invalidate the findings, which have been published in peer-reviewed journals and independently replicated in observational datasets. But it does mean the field would benefit from more independent research groups running their own interventional trials, ideally in diverse populations and with longer follow-up periods.